Internship

Biologics Co-op Program

Updated on 12/16/2024

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

No H1B Sponsorship

Devens, MA, USA

Site-essential roles require 100% of shifts onsite.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • Currently enrolled in a Science or Engineering Bachelor of Science, Masters, or Doctorate program
  • Interest and passion for BioPharma and biotechnology
  • Strong communication skills
  • Experience working in highly collaborative environment, ability to work in a team
  • Strong analytical skills as demonstrated through previous experiences which may include: laboratory experience, project design course(s), research projects, knowledge of programming/scientific software, and/or previous co-ops/internships
  • Candidates who are seeking to learn more about the process development lab space, manufacturing environment, or manufacturing support roles
  • All candidates must be authorized to work in the US at the time of hire. Please note that immigration or visa sponsorship is not available for this position.
Responsibilities
  • Knowledge or understanding of biotech process such as cell culture and purification
  • General lab skills
  • Data management
  • Process optimization
  • Development of templates/best practices
  • Strategy development

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with AI Proteins could expand BMS's therapeutic portfolio with miniprotein-based therapeutics.
  • FDA approval for Opdivo in NSCLC treatment strengthens BMS's position in lung cancer therapies.
  • Licensing agreement with Prime Medicine enhances BMS's cell and gene therapy capabilities.

What critics are saying

  • Legal challenges from the lawsuit against HRSA and HHS could harm BMS's reputation.
  • Refiling of the $6.4 billion lawsuit by UMB poses potential financial liabilities.
  • Competitive pressure in oncology as Opdivo faces competition from other PD-1 inhibitors.

What makes Bristol-Myers Squibb unique

  • BMS focuses on innovative medicines in oncology, immunology, and cardiovascular diseases.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?